ElectroCore Total Liabilities 2017-2025 | ECOR

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

ElectroCore total liabilities from 2017 to 2025. Total liabilities can be defined as the total value of all possible claims against the corporation.

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

ElectroCore total liabilities from 2017 to 2025. Total liabilities can be defined as the total value of all possible claims against the corporation.

Related Stocks
Company Name	Market Cap
Chugai Pharmaceutical (CHGCY)	$75.3B
Zoetis (ZTS)	$68.1B
Takeda Pharmaceutical (TAK)	$46.9B
Daiichi Sankyo, - (DSNKY)	$43.1B
BeOne Medicines - (ONC)	$29.6B
Sandoz Group AG (SDZNY)	$25B
Summit Therapeutics (SMMT)	$18.1B
Merck (MKKGY)	$16.5B
Shionogi (SGIOY)	$14.2B
United Therapeutics (UTHR)	$13.2B
Neurocrine Biosciences (NBIX)	$13B
Orion OYJ (ORINY)	$11B
IPSEN (IPSEY)	$10.2B
Stevanato Group S.p.A (STVN)	$7.8B
Corcept Therapeutics (CORT)	$7.6B
Madrigal Pharmaceuticals (MDGL)	$6.9B
Grifols, S.A (GRFS)	$6.7B
Ionis Pharmaceuticals (IONS)	$6.7B
Hikma Pharmaceuticals Plc (HKMPF)	$6.2B
Ono Pharmaceutical (OPHLF)	$5.3B
Soleno Therapeutics (SLNO)	$4.2B
Hypermarcas (HYPMY)	$3.2B
Crinetics Pharmaceuticals (CRNX)	$3B
AMNEAL PHARMACEUTICALS, INC (AMRX)	$2.6B
Catalyst Pharmaceuticals (CPRX)	$2.6B
NewAmsterdam Pharma (NAMS)	$2.4B
Centessa Pharmaceuticals (CNTA)	$2B
BioCryst Pharmaceuticals (BCRX)	$1.8B
Ocular Therapeutix (OCUL)	$1.8B
ARS Pharmaceuticals (SPRY)	$1.7B